

# Acute Heart Failure (AHF) Therapeutics: Market Research Report

<https://marketpublishers.com/r/A1777947F82EN.html>

Date: January 2018

Pages: 295

Price: US\$ 5,450.00 (Single User License)

ID: A1777947F82EN

## Abstracts

This report analyzes the worldwide markets for Next Generation Sequencers in US\$ Thousand. The Global market is additionally analyzed by the following End-Use Segments: Pharmaceutical/Biotech, Industrial, and Government/Academia. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022.

Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs.

The report profiles 93 companies including many key and niche players such as -

Agilent Technologies Inc.

Becton, Dickinson and Company

Fluidigm Corporation

Genomatix GmbH

Illumina, Inc.

## Contents

### I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

### II. EXECUTIVE SUMMARY

#### 1. INDUSTRY OVERVIEW

Market Outlook

**Table 1.** Number of AHF Events in the US and EU by Type: 2017E (includes corresponding Graph/Chart)

Sizing the AHF Market

Acute Heart Failure – An Overview of the Disease and Available Therapeutics

Diuretics and Vasodilators – The First Line Therapy for AHF

Other Known Drugs for AHF – Lower Efficacy Thwarts Use

#### 2. MARKET DRIVERS, TRENDS & ISSUES

Conventional Therapies Leave Considerable Unmet Needs

Novel Treatments Offer a Ray of Hope

Key AHF Therapeutics in the Pipeline

Serelaxin Nears Trial Readout from RELAX-AHF-2

Ularitide – A Novel Drug in Development for AHF

The Litany of Drug Failures Expands, Emphasis on Prevention Grows

Other Promising Drugs under Development

Research Findings

Kidney Dysfunction – Predictor of Acute Heart failure

Genetic Influence on Heart Disease among African Americans

Higher Body Mass Index – A Key Risk Factor for AHF

Supplemental Oxygen Therapy May not be for All Cases of AHF

Macro Growth Drivers

Alarming Levels of Cardiovascular Disease (CVD) Prevalence: Key Growth Driver for AHF Therapeutics

**Table 2.** Economic Burden of Cardiovascular Diseases between 2011 and 2025:

Breakdown of Lost Output Value by Income Group (includes corresponding Graph/Chart)

**Table 3.** Global Annual Medical Cost of CVD in US\$ Billion (2010-2030) (includes corresponding Graph/Chart)

**Table 4.** Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart)

**Table 5.** Fatalities in Low Income Countries by Health Disorder (2015 & 2030): Projected Percentage Breakdown of Number of Deaths for CVD; Cancer; Injury; HIV, TB & Malaria; Malnutrition; and Others (includes corresponding Graph/Chart)

**Table 6.** Fatalities in Mid Income Countries by Health Disorder (2015 & 2030): Projected Percentage Breakdown of Number of Deaths for CVD; Cancer; Injury; HIV, TB & Malaria; Malnutrition; and Others (includes corresponding Graph/Chart)

**Table 7.** Fatalities in High Income Countries by Health Disorder (2015 & 2030): Projected Percentage Breakdown of Number of Deaths for CVD, Cancer, Injury, and Others (includes corresponding Graph/Chart)

CVD: Fast Facts

Ballooning Elderly Population: The Vital Growth Driver for AHF Therapeutics

**Table 8.** Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)

**Table 9.** Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in '000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart)

**Table 10.** Life Expectancy at Birth in Years of People in Select Countries (2015E) (includes corresponding Graph/Chart)

**Table 11.** Global Life Expectancy at Birth (Years) by Geographic Region: 1950-2050 (includes corresponding Graph/Chart)

### **3. TREATMENT OF ACUTE HEART FAILURE (AHF)**

### **4. ACUTE HEART FAILURE - THE DISEASE, CAUSES, SYMPTOMS, AND EVALUATION METHODS**

Types of AHF

Causes of AHF

Coronary Heart Disease

Cardiomyopathy

High BP

Damaged Heart Valves

Patho-Physiology of AHF

Signs and Symptoms

Low Output

Fluid Overload/Congestion

Left-Sided Failure

Right-Sided Failure

Biventricular Failure

Diagnosis

Classification of AHF

Left Side and Right Side

Systolic Dysfunction and Diastolic Dysfunction

Backward and Forward Failure

Low-Output Heart Failure and High-Output Heart Failure

Functional Classification

Phases of Evaluation and Management of AHF Patients

Early/Initial Phase

In-Hospital Phase

Pre-Discharge Phase

Early Post-Discharge Phase

### **5. RECENT INDUSTRY ACTIVITY**

Capricor Terminates Licensing Deal for Cenderitide with Mayo Clinic

Renova Acquires Stresscopin from Janssen

Cytokinetics to Sell Part of Potential Royalty on omecamtiv mecarbil to Royalty Pharma

CVie Therapeutics Enrolls First Patient for Phase 2b Clinical Trial of Istaroxime

ScinoPharm and CVie Therapeutics Collaborate for New AHF Drug

Trevena's TRV027 Fails to Meet Clinical Study Endpoints

NIH Awards SBIR Grant to Madeleine Pharmaceuticals for Clinical Development of Vastiras  
Cardioentis Raises Funds to Support Competition of Phase III Trials on Ularitide for ADHF  
FDA Grants Fast Track Designation to Cardioentis' Ularitide  
Bristol-Myers Squibb Completes Acquisition of Cardioxyl  
Cardioentis Completes Enrollment in Phase III Trial of Ularitide  
Capricor Therapeutics Completes Enrollment for Phase II Trial of Cenderitide  
Cardioentis Enters into Collaboration with Roche  
Capricor Enters into Agreement to Acquire Patent Rights of Natriuretic Peptides from Medtronic  
Cardioentis Enters into €45 million Financing Agreement with HC Royalty  
USPTO Grants Patent to Trevena's TRV027  
FDA Declines Approval for Novartis' Serelaxin

## 6. FOCUS ON SELECT PLAYERS

Bayer AG (Germany)  
Bristol-Myers Squibb Company (USA)  
Cardioentis AG (Switzerland)  
CVie Therapeutics Limited (Taiwan)  
Cytokinetics, Inc. (USA)  
Merck & Co. (USA)  
Novartis AG (Switzerland)  
Orion Corporation (Finland)  
PhaseBio Pharmaceuticals, Inc. (USA)

## 7. GLOBAL MARKET PERSPECTIVE

**Table 12.** World Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 13.** World 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2016 and 2022 (includes corresponding Graph/Chart)

### III. MARKET

#### 1. THE UNITED STATES

##### A. Market Analysis

###### Market Outlook

High AHF Prevalence Drives Demand for Therapeutics

Rising Elderly Population: Key Growth Driver

**Table 14.** Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)

**Table 15.** North American Elderly Population by Age Group (1975-2050) (includes corresponding Graph/Chart)

##### Strategic Corporate Developments

###### Select Key Players

##### B. Market Analytics

**Table 16.** US Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics Market Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

#### 2. JAPAN

##### A. Market Analysis

###### Outlook

Aging Population Drive Steady Market Growth

**Table 17.** Aging Population in Japan (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)

##### A Review of Heart Failure Epidemiology in Japan

###### Japan-Exclusive Drugs Maintain the Lead

###### Regulatory Overview

##### B. Market Analytics

**Table 18.** Japanese Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics Market Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

### 3. EUROPE

#### A. Market Analysis

##### Outlook

##### Changing Demographics to Propel Market Growth

**Table 19.** European Population By Age Group (2013, 2020 & 2040): Percentage Share Breakdown of Age Groups 0-19, 20-39, 40-59, 60-79, and 80+ (includes corresponding Graph/Chart)

#### ESC Guidelines: Challenges of HFpEF Diagnosis

#### New EU Guidelines Provides Specifics of Focus for Clinical Trials

#### B. Market Analytics

**Table 20.** European Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain and Rest of European Markets Independently Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 21.** European 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain and Rest of European Markets for Years 2016 and 2022 (includes corresponding Graph/Chart)

### 3A. FRANCE

#### Market Analysis

**Table 22.** French Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics Market Analyzed with Annual Sales Figures in US\$ Thousand for Years

2015 through 2022 (includes corresponding Graph/Chart)

### **3B. GERMANY**

A. Market Analysis

Outlook

Bayer AG: Key Germany-based Global Player

B. Market Analytics

**Table 23.** German Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics Market Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

### **3C. ITALY**

Market Analysis

**Table 24.** Italian Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics Market Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

### **3D. THE UNITED KINGDOM**

A. Market Analysis

Outlook

High Levels of Awareness among the Aging Population Drives Market Growth

**Table 25.** Aging Population in the United Kingdom (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)

B. Market Analytics

**Table 26.** The UK Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics Market Analyzed with Annual Sales Figures in US\$ Thousand for Years



2015 through 2022 (includes corresponding Graph/Chart)

### **3E. SPAIN**

Market Analysis

**Table 27.** Spanish Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics Market Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

### **3F. REST OF EUROPE**

A. Market Analysis

Outlook

Heart Failure Statistics Improving in Scotland

Strategic Corporate Developments

Select Key Players

B. Market Analytics

**Table 28.** Rest of European Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics Market Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

### **4. REST OF WORLD**

A. Market Analysis

Outlook

India & China: Potential Laden Markets Offer Lucrative Opportunities

**Table 29.** Ten Largest Populated Countries Worldwide (July 2015): Total Population (in Millions) by Age Group 0-14 Years, 15-59 Years, 60+ Years for China, India, USA, Indonesia, Brazil, Pakistan, Nigeria, Bangladesh, Russia and Mexico (includes corresponding Graph/Chart)

**Table 30.** Aging Population in China (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)

**Table 31.** Aging Population in India (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)

Strategic Corporate Developments

CVie Therapeutics Limited – A Taiwan-based Developer of AHF Therapy

B. Market Analytics

**Table 32.** Rest of World Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics Market Analyzed with Annual Sales Figures in US\$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

#### **IV. COMPETITIVE LANDSCAPE**

Total Companies Profiled: 34 (including Divisions/Subsidiaries - 35)

The United States (18)

Japan (2)

Europe (10)

Germany (2)

The United Kingdom (2)

Italy (1)

Rest of Europe (5)

Asia-Pacific (Excluding Japan) (5)

## I would like to order

Product name: Acute Heart Failure (AHF) Therapeutics: Market Research Report

Product link: <https://marketpublishers.com/r/A1777947F82EN.html>

Price: US\$ 5,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A1777947F82EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970